Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Support

This activity is supported by educational grants Janssen Biotech, Inc, administered by Janssen Scientific Affairs, LLC, Sanofi Genzyme, and Takeda Oncology.

Oncology Town Hall: Primary Investigators Present Key Abstracts in Multiple Myeloma

Release Date: August 17, 2021
Expiration Date: August 17, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in multiple myeloma (MM). The treatment armamentarium for MM has expanded greatly over the last decade. As novel targeted therapies are approved in the front-line and relapsed settings, clinicians are frequently challenged with methods to personalize treatment based on patient- and disease-related factors and strategies to combine and sequence therapies to improve patient outcomes. In this educational program, experts discuss data from recently published abstracts and their effect on future treatment options and sequencing for patients with MM.

This educational activity is an archive of the live virtual symposium held on July 20, 2021.

Acknowledgement of Commercial Support

This activity is supported by educational grants Janssen Biotech, Inc, administered by Janssen Scientific Affairs, LLC, Sanofi Genzyme, and Takeda Oncology.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

These activities are intended for medical oncologists, hematologists, and other oncology health care professionals interested in the treatment of patients with MM. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals are also invited to attend.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Explain the mechanism of action of approved agents/regimens, and rationale for emerging therapeutic approaches in MM across therapy lines
  • Assess trial design, eligibility criteria, and key efficacy and safety findings from completed and ongoing pivotal studies evaluating current/emerging therapies in newly diagnosed and relapsed/refractory MM
  • Outline proactive strategies to recognize and mitigate disease-related comorbidities and treatment-associated toxicities in patients with MM
  • Evaluate the clinical implications of the latest data assessing current/emerging therapies in MM within the context of evolving treatment paradigms

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Carl Ola Landgren, MD, PhD
Carl Ola Landgren, MD, PhD
Professor of Medicine
Leonard M. Miller School of Medicine
Myeloma Program & Experimental Therapeutics Program
Tumor Biology Program
Sylvester Comprehensive Cancer Center
University of Miami
Miami, FL

Disclosures: Grant/Research Support: Amgen, Celgene, Janssen, Takeda; Other: Independent Data Monitoring Committee (IDMC) member for clinical trials by: Janssen, Takeda, and Merck.


Rafael Fonseca, MD
Rafael Fonseca, MD
Interim Executive Director
Mayo Clinic Comprehensive Cancer Center
Chief Innovation Officer
Consultant, Division of Hematology & Oncology
Getz Family Professor of Medicine
Distinguished Investigator
Mayo Clinic
Phoenix, AZ

Disclosures: Consultant: Amgen, Bristol Myers Squibb, Celgene, Takeda, Bayer, Janssen, Novartis, Pharmacyclics, Sanofi, Merck, Juno, Kite, Aduro, OncoTracker, GlaxoSmithKline, AbbVie; Other Support: Scientific Advisory Board: Adaptive Biotechnologies, OncoTracker.

Paul Richardson, MD
Paul Richardson, MD
Director of Clinical Research
Clinical Program Leader
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Grant/Research Support: Oncopeptides, Celgene/Bristol Myers Squibb, Takeda, Karyopharm; Consultant: Oncopeptides, Celgene/Bristol Myers Squibb, Takeda, Karyopharm, Janssen, Sanofi, Secura Bio, GlaxoSmithKline, Regeneron, AstraZeneca, Protocol Intelligence.

Nina Shah, MD
Nina Shah, MD
Division of Hematology-Oncology
University of California, San Francisco
San Francisco, CA

Disclosures: Grant/Research Support: Celgene/Bristol Myers Squibb, Janssen, bluebird bio, Sutro Biopharma, Teneohio, Poseida Therapeutics, Nektar Therapeutics, Precision Biosciences; Consultant: (Advisory) GlaxoSmithKline, Amgen, Indapta Therapeutics, Sanofi, CareDx, Kite, Karyopharm, Oncopeptides, CSL Behring.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By